MTOR and malignant colon neoplasm: DB-medicated CSC-inhibitory effects were associated with the decreased expression of the IGF downstream oncogenic marker, mTOR/STAT3, as well as the stemness marker, β-catenin, both of which have been reported to contribute to treatment failure and the recurrence of colon cancer [23,34,35].